logo.png
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
June 27, 2024 09:15 ET | GT Biopharma, Inc.
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...
Logo.jpg
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 21, 2024 09:15 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the...
Logo.jpg
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 15, 2024 17:00 ET | GT Biopharma, Inc.
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for...
Logo.jpg
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
March 26, 2024 17:00 ET | GT Biopharma, Inc.
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
Logo.jpg
GT Biopharma Reports Second Quarter 2023 Financial Results
August 07, 2023 09:00 ET | GT Biopharma, Inc.
Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical...
Logo.jpg
GT Biopharma Names Charles J. Casamento to the Board of Directors
May 04, 2023 09:05 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...
Logo.jpg
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
February 02, 2023 09:46 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Logo.jpg
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
December 30, 2022 08:00 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Logo.jpg
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
December 14, 2022 07:30 ET | GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
Logo.jpg
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
October 31, 2022 17:15 ET | GT Biopharma, Inc.
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...